|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Moody's Investors Service ("Moody's") assigned a Baa1 rating to the proposed senior unsecured notes offering of Zoetis Inc. ("Zoetis"). There are no changes to Zoetis' existing ratings including the Baa1 senior unsecured rating and the Prime-2 commercial paper rating. Proceeds from the notes offerings will be used to repay short term debt that was used in financing the acquisition of Abaxis, Inc. and for general corporate purposes.
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on July 16. Index (PMI) data, output in the Healthcare sector is rising.
NEW YORK , July 31, 2018 /PRNewswire/ -- Triumph Bancorp Inc. (NASD: TBK) will replace Abaxis Inc. (NASD: ABAX) in the S&P SmallCap 600 effective prior to the open of trading on Monday, August 6 . S&P ...
With the adoption of Abaxis' (ABAX) point-of-care diagnostic instruments post acquisition, the combined entity's veterinary diagnostics category should grow faster than the animal health industry.
LONDON, UK / ACCESSWIRE / July 10, 2018 / If you want access to our free research report on Zoetis Inc. (NYSE: ZTS), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ZTS as the Company's latest news hit the wire. On July 06, 2018, the Company announced that it has completed the acquisition of Abaxis, Inc. (NASDAQ: ABAX), which is a leader in the development, manufacture, and marketing of diagnostic instruments for veterinary point-of-care services, for $83.00 per share in cash, or approximately $2.0 billion in total.
On July 6, Zoetis (ZTS) and Abaxis (ABAX) announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
Zoetis Inc. (ZTS) and Abaxis, Inc. (ABAX) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection with Zoetis’ previously-announced acquisition of Abaxis for US $83.00 per share in cash, or approximately $2.0 billion in aggregate. The expiration of the waiting period under the HSR Act satisfies one of the conditions necessary for the consummation of the transaction. The transaction is subject to other customary closing conditions, including the approval of Abaxis shareholders.
We are upbeat about Abaxis' (ABAX) solid consumable and instrument sales growth along with strength in the medical and veterinary market segments.
Since Abaxis Inc (NASDAQ:ABAX) released its earnings in March 2018, analysts seem fairly confident, as a 32.86% increase in profits is expected in the upcoming year, compared with the pastRead More...
NEW YORK , June 5, 2018 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
NEW YORK , June 5, 2018 /PRNewswire/ -- Abaxis, Inc. (ABAX) Lifshitz & Miller announces investigation into possible breaches of fiduciary duties in connection with the proposed sale of Abaxis to Zoetis ...
The latest earnings release Abaxis Inc’s (NASDAQ:ABAX) announced in March 2018 showed that the business endured a immense headwind with earnings deteriorating by -17.09%. Below, I’ve presented key growth figuresRead More...
Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of Abaxis, Inc. (ABAX) by Zoetis Inc. (ZTS). On May 16, 2018, the two companies announced the signing of a definitive merger agreement pursuant to which Zoetis will acquire Abaxis. Under the terms of the agreement, Abaxis shareholders will receive $83.00 in cash for each share of Abaxis common stock.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 17) Abaxis Inc (NASDAQ: ABAX ) (rallying for second straight session ...
WeissLaw is investigating whether ABAX's Board acted to maximize shareholder value prior to entering into the agreement. Notably, at least one analyst set a target price of $90.00 per share, or $7.00 above the offer price. Additionally, ABAX recently announced positive financial results. It reported revenue of $67.9 million, representing an increase of 17% when compared to the figures reported in the same period of the previous year.
Post takeover of Abaxis' (ABAX) point-of-care diagnostic instruments, Zoetis expects the consolidated company's veterinary diagnostics category to speed up growth over the animal health industry.